Reuters logo
BRIEF-‍Novartis announces phase three strive data published in NEJM
November 29, 2017 / 10:06 PM / 18 days ago

BRIEF-‍Novartis announces phase three strive data published in NEJM

Nov 29 (Reuters) - Novartis Ag:

* ‍NOVARTIS ANNOUNCES PHASE III STRIVE DATA PUBLISHED IN NEJM DEMONSTRATING SIGNIFICANT AND SUSTAINED EFFICACY OF ERENUMAB IN MIGRAINE PREVENTION​

* NOVARTIS - NEJM PUBLISHED POSITIVE RESULTS FROM 6-MONTH PHASE III STRIVE STUDY EVALUATING ERENUMAB IN PREVENTION OF EPISODIC MIGRAINE​

* - ‍ERENUMAB DELIVERED CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT DIFFERENCES FROM PLACEBO FOR ALL PRIMARY AND SECONDARY ENDPOINTS​

* ‍FIFTY PERCENT OF PATIENTS TAKING ERENUMAB 140MG HAD THEIR MIGRAINE DAYS CUT BY AT LEAST HALF​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below